Acetylcholine News and Research RSS Feed - Acetylcholine News and Research

Long-term suppression of neurotransmitter acetylcholine may lead to dementia-like changes in the brain

Long-term suppression of neurotransmitter acetylcholine may lead to dementia-like changes in the brain

A new study from Western University is helping to explain why the long-term use of common anticholinergic drugs used to treat conditions like allergies and overactive bladder lead to an increased risk of developing dementia later in life. [More]
Study suggests how expression, function of nAChRs regulated in AD

Study suggests how expression, function of nAChRs regulated in AD

Nicotinic acetylcholine receptors (nAChRs) have been pursued for decades as potential molecular targets to treat cognitive dysfunction in Alzheimer's disease (AD) due to their demonstrated role in processes underlying cognition such as synaptic facilitation, and theta and gamma wave activity. [More]
Nutritional supplements can enhance effectiveness of antidepressants

Nutritional supplements can enhance effectiveness of antidepressants

An international evidence review has found that certain nutritional supplements can increase the effectiveness of antidepressants for people with clinical depression. [More]
FAU's clinical trial to evaluate efficacy of RVT-101 tablet for Lewy body dementia

FAU's clinical trial to evaluate efficacy of RVT-101 tablet for Lewy body dementia

Florida Atlantic University's Charles E. Schmidt College of Medicine is spearheading the South Florida site for the first U.S. clinical trial for Lewy body dementia (LBD), the second-most common dementia after Alzheimer's disease. The HEADWAY-DLB is a phase 2b multi-center, double-blind, placebo-controlled study to evaluate an investigational medicine, RVT-101, for dementia with Lewy bodies. [More]
Scientists identify unique memory suppressor gene that could provide clues for new Alzheimer’s disease treatments

Scientists identify unique memory suppressor gene that could provide clues for new Alzheimer’s disease treatments

While research has identified hundreds of genes required for normal memory formation, genes that suppress memory are of special interest because they offer insights into how the brain prioritizes and manages all of the information, including memories, that it takes in every day. [More]
Study explores two new antibodies believed to cause myasthenia gravis

Study explores two new antibodies believed to cause myasthenia gravis

A study of patients from across the nation with myasthenia gravis is helping determine the incidence of two new antibodies believed to cause the disease, and whether these patients need different treatment strategies. [More]
Kanazawa University researchers identify molecular mechanism that links liver disease and obesity

Kanazawa University researchers identify molecular mechanism that links liver disease and obesity

Kanazawa University researchers find similarities in the impeded signalling between central insulin activity and glucose production in the liver for both obese mice and mice that have had the vagus nerve removed. [More]
New vaccine delays effects of nicotine within first 10 minutes after injection

New vaccine delays effects of nicotine within first 10 minutes after injection

Many people who smoke want to quit, but the urge to light up is often irresistible. An effective vaccine to help people kick the habit once and for all has been elusive. But now, scientists report in ACS' Journal of Medicinal Chemistry a new vaccine design that could help achieve this goal. [More]
New discoveries reveal why smokers have increased risk of type 2 diabetes

New discoveries reveal why smokers have increased risk of type 2 diabetes

Researchers at Lund University in Sweden have made two new discoveries with regard to the beta cells' ability to release insulin. The findings can also provide a possible explanation as to why smokers have an increased risk of type 2 diabetes. [More]
Longer, more intense period of rehabilitation may boost recovery after stroke or traumatic injury

Longer, more intense period of rehabilitation may boost recovery after stroke or traumatic injury

Cognitive and functional recovery after a stroke or traumatic injury requires intense rehabilitative therapy to help the brain repair and restructure itself. New findings by researchers at University of California, San Diego School of Medicine report that not only is rehabilitation vital - in an animal model, rats with cortical injury that did not receive intensive rehab did not rebuild brain structure or recover function - but that a longer, even more intense period of rehabilitation may produce even greater benefit. [More]
FDA-approved Alzheimer's medications may help people quit smoking

FDA-approved Alzheimer's medications may help people quit smoking

Despite several safe drug therapies available to help smokers quit, three-quarters report relapsing within six months of a quit attempt. University of Pennsylvania researchers Rebecca Ashare and Heath Schmidt saw potential for a permanent cessation solution in a class of FDA-approved medications used to improve cognitive impairments from Alzheimer's disease. [More]
Researchers devise lipid-based diets to relieve symptoms of Alzheimer's disease

Researchers devise lipid-based diets to relieve symptoms of Alzheimer's disease

Alzheimer´s disease (AD) is the most common disease underlying memory problems and dementia in the elderly. One of the invariable pathologies in AD is degeneration of cholinergic synapses in brain cortex and hippocampus. [More]
Vestibular test may aid ocular myasthenia gravis diagnosis

Vestibular test may aid ocular myasthenia gravis diagnosis

Assessing extraocular muscle activity by recording ocular vestibular evoked myogenic potentials is a promising test for isolated ocular myasthenia gravis, report researchers. [More]
Anticholinergic medications may not be best option for dementia patients in rehab facility

Anticholinergic medications may not be best option for dementia patients in rehab facility

During rehabilitation following an acute hospital stay, medications that block neurotransmitters may be overprescribed to older patients suffering from delirium superimposed on dementia, according to health researchers. [More]
Anticholinesterase offers a ‘steadying hand’ to PD patients

Anticholinesterase offers a ‘steadying hand’ to PD patients

The dementia drug rivastigmine may reduce the risk of falls in patients with Parkinson’s disease by improving gait stability, findings from the phase II ReSponD trial show. [More]
Oral drug rivastigmine could help prevent falls in people with Parkinson’s

Oral drug rivastigmine could help prevent falls in people with Parkinson’s

Scientists have discovered that a commonly prescribed dementia drug could hold the key to helping prevent debilitating falls for people with Parkinson’s. [More]
Small differences in specific genetic variant could alter nicotine consumption

Small differences in specific genetic variant could alter nicotine consumption

Nicotine is an addictive substance and genetic factors are known to play a role in smoking behaviors. Recently, a team of researchers at Penn State and the University of Colorado determined how small differences in a particular region of the mouse genome can alter nicotine consumption. [More]
Bionomics plans to launch BNC210 Phase 2 trial for treatment of PTSD

Bionomics plans to launch BNC210 Phase 2 trial for treatment of PTSD

Australian drug development company Bionomics Limited will launch a key Phase 2 trial of its novel anxiety drug BNC210 as a treatment for post-traumatic stress disorder (PTSD), following a US$12 million private placement to US institutional investors. [More]
Novel method for examining small molecules may provide platform for new drug design

Novel method for examining small molecules may provide platform for new drug design

Most pharmaceutical drugs consist of tiny molecules, which target a class of proteins found on the surfaces of cell membranes. Studying these subtle interactions is essential for the design of effective drugs, but the task is extremely challenging. [More]
Bionomics, Merck extend collaboration to develop drug candidates for treatment of chronic and neuropathic pain

Bionomics, Merck extend collaboration to develop drug candidates for treatment of chronic and neuropathic pain

Bionomics Limited, a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system (CNS) and cancer, today announced that it has extended its strategic collaboration with Merck & Co., Inc., Kenilworth NJ., (known as MSD outside the United States and Canada) for the discovery and development of drug candidates for the treatment of chronic and neuropathic pain. [More]
Advertisement
Advertisement